Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma
about
The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment.Novel tyrosine kinase inhibitors for renal cell carcinoma.Recurrent MET fusion genes represent a drug target in pediatric glioblastoma.Prevention of BMS-777607-induced polyploidy/senescence by mTOR inhibitor AZD8055 sensitizes breast cancer cells to cytotoxic chemotherapeutics.Distinct brain responses to different inhibitions: Evidence from a modified Flanker Task.Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation.
P2860
Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Initial clinical sensitivity a ...... papillary renal cell carcinoma
@en
type
label
Initial clinical sensitivity a ...... papillary renal cell carcinoma
@en
prefLabel
Initial clinical sensitivity a ...... papillary renal cell carcinoma
@en
P2093
P2860
P356
P1476
Initial clinical sensitivity a ...... papillary renal cell carcinoma
@en
P2093
D Ross Camidge
Eric F P M Schoenmakers
James G Christensen
Jeffrey W Clark
Jennifer R Diamond
Keith A Ching
Keith Wilner
Ling-Guo Xu
Marileila Varella-Garcia
Maruja E Lira
P2860
P304
P356
10.1200/JCO.2012.46.4289
P407
P50
P577
2013-04-22T00:00:00Z